January 25, 2020

FDA Approves New Drug for MS Treatment

The United States Food and Drug Administration announced on March 27, 2013 that it has approved the drug Tecfidera to treat adults with relapsing forms of multiple sclerosis symptoms.  The drug activates a chemical pathway in the body known as NrF2 that protects nerve cells from inflammation.

Pharmaceutical manufacturer Biogen will begin distributing Tecfidera within the next few months.

Researchers believe that Tecfidera may decrease a patient’s white blood cell count and thus reduce inflammation when a patient’s immune system attacks healthy nerve cells. Results from clinical trials suggest that Tecfidera may slow down the progress of MS symptoms.

Tecfidera is reported to produce mild side effects, which diminish over time.  In a Social Security disability context, administrative law judges expect MS patients to comply with their doctors’ instructions regarding medications.

The FDA regularly evaluates new medicines that have been developed by pharmaceutical companies.  Here is a link to a page on the FDA site which identifies current new approvals.

Speak Your Mind